drugset / Trial / NCT00106262
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
Phase 2
Terminated
38 enrolled
Women and Infants Hospital of Rhode Island
Millennium Pharmaceuticals, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is conducting an evaluation of two chemotherapy drugs, Velcade and Irinotecan, in women with advanced, recurrent, or metastatic cervical cancer, vaginal cancer, or vulvar cancer. Patients with cervical cancer may have received a platinum-containing treatment as systemic therapy without radiation, but is not required.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-03
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |